|
1
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. New Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paniccia A, Hosokawa P, Henderson W,
Schulick RD, Edil BH, McCarter MD and Gajdos C: Characteristics of
10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg.
150:701–710. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Conlon KC, Klimstra DS and Brennan MF:
Long-term survival after curative resection for pancreatic ductal
adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann
Surg. 223:273–279. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jin C, Yao L, Long J, Fu DL, Yu XJ, Xu J,
Yang F and Ni QX: Effect of multiple-phase regional intra-arterial
infusion chemotherapy on patients with resectable pancreatic head
adenocarcinoma. Chinese Med J (Engl). 122:284–290. 2009.
|
|
6
|
Sasada T, Denno R, Tanaka T, Kanai M,
Mizukami Y, Kohno S and Takabayashi A: Intra-arterial infusion
chemotherapy with 5-fluorouracil and cisplatin in advanced
pancreatic cancer: A feasibility study. Am J Clin Oncol. 31:71–78.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi S, Yao WT, Xu J, Long J, Liu C and Yu
XJ: Combinational therapy: New hope for pancreatic cancer? Cancer
Lett. 317:127–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohigashi H, Ishikawa O, Imaoka S, Sasaki
Y, Kabuto T, Kameyama M, Furukawa H, Hiratuka M, Nakamori S, Nakano
H, et al: A new method of intra-arterial regional chemotherapy with
more selective drug delivery for locally advanced pancreatic
cancer. Hepatogastroenterology. 43:338–345. 1996.PubMed/NCBI
|
|
9
|
Swords DS, Firpo MA, Scaife CL and
Mulvihill SJ: Biomarkers in pancreatic adenocarcinoma: Current
perspectives. Onco Targets Ther. 9:7459–7467. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Raposo G and Stoorvogel W: Extracellular
vesicles: Exosomes, microvesicles, and friends. J Cell Biol.
200:373–383. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van der Pol E, Böing AN, Harrison P, Sturk
A and Nieuwland R: Classification, functions, and clinical
relevance of extracellular vesicles. Pharmacol Rev. 64:676–705.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sharma A, Khatun Z and Shiras A: Tumor
exosomes: Cellular postmen of cancer diagnosis and personalized
therapy. Nanomedicine (Lond). 11:421–437. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Melo SA, Luecke LB, Kahlert C, Fernandez
AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari
N, et al: Glypican-1 identifies cancer exosomes and detects early
pancreatic cancer. Nature. 523:177–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kayed H, Kleeff J, Keleg S, Jiang XH,
Penzel R, Giese T, Zentgraf H, Büchler MW, Korc M and Friess H:
Correlation of glypican-1 expression with TGF-beta, BMP, and
activin receptors in pancreatic ductal adenocarcinoma. Int J Oncol.
29:1139–1148. 2006.PubMed/NCBI
|
|
15
|
Duan L, Hu XQ, Feng DY, Lei SY and Hu GH:
GPC-1 may serve as a predictor of perineural invasion and a
prognosticator of survival in pancreatic cancer. Asian J Surg.
36:7–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li C, Du X, Tai S, Zhong X, Wang Z, Hu Z,
Zhang L, Kang P, Ji D, Jiang X, et al: GPC1 regulated by miR-96-5p,
rather than miR-182-5p, in inhibition of pancreatic carcinoma cell
proliferation. Int J Mol Sci. 15:6314–6327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kleeff J, Ishiwata T, Kumbasar A, Friess
H, Büchler MW, Lander AD and Korc M: The cell-surface heparan
sulfate proteoglycan glypican-1 regulates growth factor action in
pancreatic carcinoma cells and is overexpressed in human pancreatic
cancer. J Clin Invest. 102:1662–1673. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu FH, Tang Y, Sun J, Yuan Z, Li S, Sheng
J, Ren H and Hao J: Regional intra-arterial vs. systemic
chemotherapy for advanced pancreatic cancer: A systematic review
and meta-analysis of randomized controlled trials. PloS One.
7:e408472012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Yang X, Zhou G, Chen Y, Li C and
Wang X: Gemcitabine-based regional intra-arterial infusion
chemotherapy in patients with advanced pancreatic adenocarcinoma.
Medicine (Baltimore). 95:e30982016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Corke C and Cranswick P: A Seldinger
technique for minitracheostomy insertion. Anaesth Intensive Care.
16:206–207. 1988.PubMed/NCBI
|
|
21
|
Katz MH, Hwang R, Fleming JB and Evans DB:
Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA
Cancer J Clin. 58:111–125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Enderle D, Spiel A, Coticchia CM, Berghoff
E, Mueller R, Schlumpberger M, Sprenger-Haussels M, Shaffer JM,
Lader E, Skog J and Noerholm M: Characterization of RNA from
exosomes and other extracellular vesicles isolated by a novel spin
column-based method. PloS One. 10:e01361332015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nazli O, Bozdag AD, Tansug T, Kir R and
Kaymak E: The diagnostic importance of CEA and CA 19-9 for the
early diagnosis of pancreatic carcinoma. Hepatogastroenterology.
47:1750–1752. 2000.PubMed/NCBI
|
|
24
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mohammed S, Van Buren G II and Fisher WE:
Pancreatic cancer: Advances in treatment. World J Gastroenterol.
20:9354–9360. 2014.PubMed/NCBI
|
|
26
|
Davis JL, Pandalai P, Ripley RT, Langan
RC, Steinberg SM, Walker M, Toomey MA, Levy E and Avital I:
Regional chemotherapy in locally advanced pancreatic cancer: RECLAP
trial. Trials. 12:1292011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Colombo M, Raposo G and Théry C:
Biogenesis, secretion, and intercellular interactions of exosomes
and other extracellular vesicles. Annu Rev Cell Dev Biol.
30:255–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Muñoz Martín AJ, Adeva J, Martínez-Galán
J, Reina JJ and Hidalgo M: Pancreatic ductal adenocarcinoma:
Metastatic disease. Clin Transl Oncol. 19:1423–1429. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Conroy T, Bachet JB, Ayav A, Huguet F,
Lambert A, Caramella C, Maréchal R, Van Laethem JL and Ducreux M:
Current standards and new innovative approaches for treatment of
pancreatic cancer. Eur J Cancer. 57:10–22. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cardenes HR, Chiorean EG, Dewitt J,
Schmidt M and Loehrer P: Locally advanced pancreatic cancer:
Current therapeutic approach. Oncologist. 11:612–623. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Madiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Z, Ren ZG, Ma NY, Zhao JD, Zhang Z,
Ma XJ, Long J, Xu J and Jiang GL: Intensity modulated radiotherapy
for locally advanced and metastatic pancreatic cancer: A
mono-institutional retrospective analysis. Radiat Oncol. 10:142015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takamori H, Kanemitsu K, Tsuji T, Tanaka
H, Chikamoto A, Nakahara O, Hiraoka T, Ikeda O, Kudo K, Imuta M and
Yamashita Y: 5-fluorouracil intra-arterial infusion combined with
systemic gemcitabine for unresectable pancreatic cancer. Pancreas.
30:223–226. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Muchmore JH, Preslan JE and George WJ:
Regional chemotherapy for inoperable pancreatic carcinoma. Cancer.
78 3 Suppl:S664–S673. 1996. View Article : Google Scholar
|
|
35
|
Torres C, Perales S, Alejandre MJ,
Iglesias J, Palomino RJ, Martin M, Caba O, Prados JC, Aránega A,
Delgado JR, et al: Serum cytokine profile in patients with
pancreatic cancer. Pancreas. 43:1042–1049. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Y, Yang J, Li H, Wu Y, Zhang H and
Chen W: Tumor markers CA19-9, CA242 and CEA in the diagnosis of
pancreatic cancer: A meta-analysis. Int J Clin Exp Med.
8:11683–11691. 2015.PubMed/NCBI
|
|
37
|
Grønborg M, Kristiansen TZ, Iwahori A,
Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins
MG, et al: Biomarker discovery from pancreatic cancer secretome
using a differential proteomic approach. Mol Cell Proteomics.
5:157–171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang L, Farrell JJ, Zhou H, Elashoff D,
Akin D, Park NH, Chia D and Wong DT: Salivary transcriptomic
biomarkers for detection of resectable pancreatic cancer.
Gastroenterology. 138(949–957): e1–e7. 2010. View Article : Google Scholar
|
|
39
|
Kalluri R: The biology and function of
exosomes in cancer. J Clin Invest. 126:1208–1215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Muller L, Hong CS, Stolz DB, Watkins SC
and Whiteside TL: Isolation of biologically-active exosomes from
human plasma. J Immunol Methods. 411:55–65. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kalra H, Adda CG, Liem M, Ang CS, Mechler
A, Simpson RJ, Hulett MD and Mathivanan S: Comparative proteomics
evaluation of plasma exosome isolation techniques and assessment of
the stability of exosomes in normal human blood plasma. Proteomics.
13:3354–3364. 2013. View Article : Google Scholar : PubMed/NCBI
|
